HK1198517A1 - Polyoma virus jc peptides and proteins in vaccination and diagnostic applications jc - Google Patents

Polyoma virus jc peptides and proteins in vaccination and diagnostic applications jc

Info

Publication number
HK1198517A1
HK1198517A1 HK14112523.5A HK14112523A HK1198517A1 HK 1198517 A1 HK1198517 A1 HK 1198517A1 HK 14112523 A HK14112523 A HK 14112523A HK 1198517 A1 HK1198517 A1 HK 1198517A1
Authority
HK
Hong Kong
Prior art keywords
vaccination
peptides
proteins
diagnostic applications
polyoma virus
Prior art date
Application number
HK14112523.5A
Other languages
English (en)
Chinese (zh)
Inventor
Ilijas Jelcic
Sven Schippling
Sara Yousef
Roland Martin
Mireia Sospedra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198517A1 publication Critical patent/HK1198517A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK14112523.5A 2011-07-22 2014-11-28 Polyoma virus jc peptides and proteins in vaccination and diagnostic applications jc HK1198517A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11006031A EP2548567A1 (en) 2011-07-22 2011-07-22 Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
PCT/EP2012/064445 WO2013014134A2 (en) 2011-07-22 2012-07-23 Polyoma virus jc peptides and proteins in vaccination and diagnostic applications

Publications (1)

Publication Number Publication Date
HK1198517A1 true HK1198517A1 (en) 2015-05-15

Family

ID=46548481

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112523.5A HK1198517A1 (en) 2011-07-22 2014-11-28 Polyoma virus jc peptides and proteins in vaccination and diagnostic applications jc

Country Status (12)

Country Link
US (1) US9738690B2 (xx)
EP (2) EP2548567A1 (xx)
JP (1) JP2014520877A (xx)
KR (1) KR20140062702A (xx)
CN (1) CN103826653A (xx)
AU (1) AU2012288955B2 (xx)
BR (1) BR112014001516A2 (xx)
CA (1) CA2842543A1 (xx)
EA (1) EA201490322A1 (xx)
HK (1) HK1198517A1 (xx)
MX (1) MX2014000776A (xx)
WO (1) WO2013014134A2 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2791162A2 (en) * 2011-12-12 2014-10-22 Janssen Diagnostics BVBA Polyomavirus peptide sequences
WO2014201034A2 (en) * 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment for polyomavirus infection
US9931393B2 (en) 2013-12-20 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic JC polyomavirus compositions and methods of use
EP2926831A1 (en) * 2014-03-31 2015-10-07 Ruprecht-Karls-Universität Heidelberg CD8+ T-cell epitopes from polyomavirus capsid protein VP1 for vaccination
WO2016073595A1 (en) * 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
WO2016104046A1 (ja) * 2014-12-22 2016-06-30 日東電工株式会社 透明導電性フィルム
IT201600083859A1 (it) * 2016-08-09 2018-02-09 Univ Degli Studi Di Ferrara Immunosaggio per l’identificazione di anticorpi contro il virus Polioma JC (JCPyV) mediante l’uso di peptidi sintetici.
CN113278634B (zh) * 2020-11-16 2022-06-28 艾棣维欣(苏州)生物制药有限公司 一种预防和治疗默克尔细胞癌的新型疫苗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3767755B2 (ja) * 1995-06-23 2006-04-19 エーザイ株式会社 抗ｊｃウイルス抗体
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
DE10131145B4 (de) 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
JP4840792B2 (ja) * 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療
AU2003238008A1 (en) * 2002-06-12 2003-12-31 Temple University Of The Commonwealth System Of Higher Education Method of cell growth inhibition with agnoprotein
JP2005341864A (ja) * 2004-06-02 2005-12-15 Japan Science & Technology Agency Ｊｃウイルスの粒子形成阻害剤
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
EP2054081A4 (en) 2006-08-31 2010-07-21 Baylor Res Inst VACCINE AGAINST THE JC VIRUS
CN100595765C (zh) * 2008-06-30 2010-03-24 腾讯科技（深圳）有限公司 基于媒体播放器的关键词内容发布方法及系统
CN104316696A (zh) 2009-02-05 2015-01-28 生物基因Idecma公司 用于检测jc多瘤病毒的方法
US8415150B2 (en) 2009-02-24 2013-04-09 The Trustees Of The University Of Pennsylvania Methods for treating progressive multifocal leukoencephalopathy (PML)
EP2226392A1 (en) * 2009-03-03 2010-09-08 Assistance Publique - Hôpitaux de Paris Method for detecting JCV infection
WO2011124652A1 (en) * 2010-04-08 2011-10-13 Fondazione Centro San Raffaele Del Monte Tabor Immunodominant peptide of polyomavirus jc and uses thereof

Also Published As

Publication number Publication date
CN103826653A (zh) 2014-05-28
CA2842543A1 (en) 2013-01-31
EP2734218A2 (en) 2014-05-28
JP2014520877A (ja) 2014-08-25
BR112014001516A2 (pt) 2017-02-14
NZ620196A (en) 2016-10-28
MX2014000776A (es) 2014-11-26
AU2012288955B2 (en) 2017-06-08
US9738690B2 (en) 2017-08-22
AU2012288955A1 (en) 2014-02-20
EA201490322A1 (ru) 2014-05-30
EP2548567A1 (en) 2013-01-23
WO2013014134A2 (en) 2013-01-31
KR20140062702A (ko) 2014-05-26
US20140356320A1 (en) 2014-12-04
WO2013014134A3 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
IL230918A0 (en) Modified proteins and peptides
HK1198517A1 (en) Polyoma virus jc peptides and proteins in vaccination and diagnostic applications jc
HK1200871A1 (en) Modified dna-binding proteins and uses thereof dna-
HK1200489A1 (en) Recombinant human naglu protein and uses thereof naglu
IL279676A (en) Recombinant proteins and therapeutic uses
EP2661442A4 (en) MONOMERS AND MULTIMES IMMUNOGENE PEPTIDES
HRP20181439T1 (hr) Cjepivo protiv modificiranog virusa sendai i vizualizacijski vektor
PL2668205T3 (pl) Peptydy pochodzące z ludzkiej laktoferyny i ich zastosowanie
IL229956B (en) 1mphosph peptides and ingredients containing them
HK1168622A1 (en) Antigen peptide and use thereof
EP2762487A4 (en) GLUTEN IMMUNOGENIC PEPTIDE AND ITS APPLICATIONS
ZA201303886B (en) Tomm34 peptides and vaccines including the same
EP2653477A4 (en) ACTIVE SKORPIONEPEPTIDES AND MANUFACTURING METHODS AND APPLICATIONS THEREOF
IL221474A0 (en) Hjurp peptides and vaccines including the same
EP2553096A4 (en) ECT2 PEPTIDES AND VACCINES COMPRISING THEM
IL225552A0 (en) wdhd1 peptides and vaccines containing them
IL225553A0 (en) 54orf18c peptides and vaccines containing them
GB201121233D0 (en) Modified proteins and peptides
GB201121226D0 (en) Modified proteins and peptides
GB201121236D0 (en) Proteins and peptides
GB201117876D0 (en) Peptides and their use in treatment